ALLEN HUBERT L
Known title: EXECUTIVE VICE PRESIDENTCIK: 0001565916
Associated companies
Transaction History
| ABT | ▼ Sell | Tax Withholding | 8,382 | $1.1M | 2/28/2025 | View on chart |
| ABT | ▲ Buy | Grant | 15,475 | $0 | 2/25/2025 | View on chart |
| ABT | ▲ Buy | Option Exercise | 58,428 | $2.2M | 1/30/2025 | View on chart |
| ABT | ▼ Sell | Open Market | 58,428 | $7.5M | 1/30/2025 | View on chart |
| ABT | ▲ Buy | Option Exercise | 131,360 | $5.0M | 1/29/2025 | View on chart |
| ABT | ▼ Sell | Open Market | 131,360 | $16.9M | 1/29/2025 | View on chart |
| ABT | ▼ Sell | Open Market | 150,271 | $17.6M | 10/21/2024 | View on chart |
| ABT | ▲ Buy | Option Exercise | 157,421 | $7.4M | 10/21/2024 | View on chart |
| ABT | ▼ Sell | Open Market | 1,249 | $148K | 10/21/2024 | View on chart |
| ABT | ▼ Sell | Open Market | 5,901 | $697K | 10/21/2024 | View on chart |
| ABT | ▼ Sell | Open Market | 853 | $101K | 3/1/2024 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 8,214 | $986K | 2/29/2024 | View on chart |
| ABT | ▲ Buy | Grant | 17,914 | $0 | 2/21/2024 | View on chart |
| ABT | ▼ Sell | Open Market | 1,069 | $108K | 3/1/2023 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 8,515 | $850K | 2/28/2023 | View on chart |
| ABT | ▲ Buy | Grant | 18,448 | $0 | 2/17/2023 | View on chart |
| ABT | ▼ Sell | Open Market | 1,450 | $171K | 3/1/2022 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 9,878 | $1.2M | 2/28/2022 | View on chart |
| ABT | ▲ Buy | Grant | 20,385 | $0 | 2/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Abbott Launches Ensure Max Protein Ahead of Q3 Earnings
Abbott Laboratories is launching Ensure Max Protein, a move that tests recent views on the stock's valuation. With Q3 earnings approaching, investors are watching estimates beyond just revenue and EPS. The company remains a notable dividend aristocrat, contributing to income-focused portfolios despite a trailing P/E of 33.4.
Abbott Launches Ensure Max Protein Ahead of Q3 Earnings. Abbott Laboratories is launching Ensure Max Protein, a move that tests recent views on the stock's valuation. With Q3 earnings approaching, investors are watching estimates beyond just revenue and EPS. The company remains a notable dividend aristocrat, contributing to income-focused portfolios despite a trailing P/E of 33.4.